Glatiramer acetate
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Glatiramer acetate. Glatiramer acetate competes with myelin basic protein (MBP). Fully referenced neurology checklist.
Mode of action
- Glatiramer acetate competes with myelin basic protein (MBP)
- It blocks the myelin damage caused by B cells
Dosing
Locked: subscribe to see this section.
Dermatological side effects
Locked: subscribe to see this section.
Other side effects
Locked: subscribe to see this section.
Monitoring
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis – a review of approved medications. Eur J Neurol 2016; 23(Suppl 1):18-27.
- Rice CM. Disease modification in multiple sclerosis: an update. Pract Neurol 2014; 14:6-13.
- Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45:1268-1276.
- Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1503-1511.
- Dargahi N, Katsara M, Tselios T, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci 2017; 7(7) pii: E78.
- And 4 more. Subscribe to see the full list
